Skip to content

Trial Assessing the Effect of Preoperative Furosemide on Intraoperative Blood Pressure

Randomized Controlled Trial Assessing the Effect of Preoperative Furosemide on Intraoperative Blood Pressure

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00115726
Enrollment
198
Registered
2005-06-24
Start date
2000-09-30
Completion date
2007-04-30
Last updated
2008-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congestive Heart Failure, Edema, Hypertension, Hypotension

Keywords

anesthesia, hypotension, furosemide, blood pressure, peripheral edema, diuretic, surgery, congestive heart failure

Brief summary

The purpose of this study is to determine whether continuing or discontinuing furosemide (a diuretic) on the day of elective noncardiac surgery for those who take furosemide on a chronic basis, causes more intraoperative hypotension (low blood pressure) during surgery. Our hypothesis is that the usual practice of continuing furosemide on the day of surgery would contribute to more hypotension during surgery than discontinuing furosemide.

Detailed description

A significant proportion of patients who undergo surgery take medications on a chronic basis. Little is known about the effects of these medications on the successful conduct of anesthesia and surgery. Diuretics like furosemide may contribute to low blood pressure during surgery, an outcome associated with cardiovascular complications. However, many patients are recommended to take their diuretics on the day of surgery. We wished to determine if preoperative administration of furosemide contributes to intraoperative hypotension compared to placebo. Comparison: We conducted a randomized, double blind placebo controlled trial to compare the effect of furosemide with that of placebo on intraoperative hypotension using intraoperative blood pressure recordings in patients who take furosemide chronically and were undergoing noncardiac surgery.

Interventions

DRUGfurosemide

for patients on chronic furosemide therapy, patients are randomized to furosemide (at their previous dose) or placebo (given in identical form to ensure masking)

DRUGplacebo

patients will be given placebo capsules (identical to experimental arm in color) at the equivalent dose as to their chronic furosemide therapy.

Sponsors

The Centre for the Advancement of Health
CollaboratorUNKNOWN
University of Calgary
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All adults referred to preoperative assessment clinics by surgeons for elective non-cardiac surgery who routinely take furosemide. * Participants must also be able to give informed consent

Exclusion criteria

* Less than 18 years of age * Have comorbid conditions with which brief periods of hypotension may be particularly harmful such as: 1) pregnancy; 2) baseline hypotension (systolic \<100 mmHg at the preoperative assessment clinic); 3) autonomic dysfunction; 4) severe aortic stenosis. * Patients who take furosemide only on an 'as needed basis' rather than 'regularly'. * Those patients who take less than 10 mg of furosemide daily * Those patients who are undergoing local anesthetic only surgical procedures * Patients who are unwilling or unable to give informed consent.

Design outcomes

Primary

MeasureTime frame
Proportion of patients developing hypotension during the operative period. Hypotension is defined based on blood pressure criteria (systolic BP <90 mmHg or 35% drop in mean arterial pressure) (or vasopressor treatment during surgery).hospital stay

Secondary

MeasureTime frame
Patients will be followed up for the duration of their hospital stay for the following endpoints: (1) Development of congestive heart failure exacerbationhospital stay
(2) Total cardiovascular complications: composite of acute myocardial infarction, angina, stroke/TIA, arrhythmia, congestive heart failure or cardiac death.hospital stay

Countries

Canada, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026